Reuters logo
BRIEF-Glycomimetics reports supportive biomarker data from early-stage trial of GMI-1271
2017年5月18日 / 上午11点13分 / 6 个月前

BRIEF-Glycomimetics reports supportive biomarker data from early-stage trial of GMI-1271

May 18 (Reuters) - GlycoMimetics Inc-

* GlycoMimetics announces high overall response rates, low induction mortality, promising initial survival outcomes, and supportive biomarker data from phase 1/2 trial of GMI-1271 in AML Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below